BOULDER, COLORADO – October 22, 2025 – VitriVax, Inc., a vaccine formulation technology company, today announced it raised a total of $17.25 million in Series B financing. The round was co-led by Adjuvant Capital and RA Capital Management, LP. Proceeds from the financing will be used for the continued development and commercialization of VitriVax’s proprietary Atomic Layering Thermostable Antigen and Adjuvant (ALTA®) technology.

“The completion of our Series B financing marks an important milestone for VitriVax as we continue to advance the development of ALTA®, our thermostable, single-shot vaccine platform,” said Romulo Colindres, Chief Executive Officer of VitriVax. “This funding positions us well to execute on our regulatory and clinical strategies, bringing us closer to addressing critical needs in vaccine access and immunization coverage.”

Vaccines have transformed global health, yet significant challenges remain in ensuring equitable access and effective immunization. Many vaccines require strict cold-chain storage, making distribution to remote or resource-limited regions difficult and costly. Additionally, vaccines may require multiple doses, which can pose logistical hurdles and increase healthcare burdens. Designed to eliminate the need for cold-chain dependencies and enable a single-shot formulation for vaccines with dosing schedules, VitriVax’s ALTA® platform has the potential to increase access to lifesaving immunizations worldwide by simplifying distribution and vaccination schedules.

“We are pleased to support VitriVax as they work to address critical challenges in vaccine development and delivery,” said Glenn Rockman, Founder and Managing Partner at Adjuvant Capital. “Thermostable, single-administration products have the potential to shift the paradigm in how vaccines are distributed and administered, potentially accelerating many long-sought public health goals.”

The Series B capital raise follows a $9.9 million grant from the Gates Foundation, which will support aseptic manufacturing of VitriVax’s ALTA^® technology. The grant will enable Phase 1-ready GMP manufacturing and advance the platform to prepare for first-in-human clinical trials. In addition to grant funding from the Gates Foundation, VitriVax has also received a grant from the Coalition for Epidemic Preparedness Initiatives (CEPI), along with a significant multi-year contract from the Department of Defense.

About VitriVax

VitriVax, headquartered in Boulder, Colorado, is a vaccine formulation technology company that engineers innovative solutions to maximize the global accessibility and utility of human vaccines—vaccines that save lives and protect our world from preventable disease.

Media Contact:

Julia Fuller

Julia@Fullercomms.com

858-692-2001

BOULDER, COLORADO – October 14, 2025 – VitriVax, Inc., a vaccine formulation technology company, today announced it has been awarded a two-year, $9.9 million grant from the Gates Foundation. The funding will support the scale-up of VitriVax’s Atomic Layering Thermostable Antigen and Adjuvant (ALTA^®) technology, enabling Phase 1-ready GMP manufacturing and advancing the platform to prepare for Phase 1 clinical trials.

Within the scope of this grant, VitriVax will work with a Contract Development and Manufacturing Organization (CDMO) suited for early-phase clinical production. The work includes preparation and execution of manufacturing and regulatory activities in support of future clinical development of an ALTA^®-enabled vaccine.

“This grant enables us to take ALTA^® from lab-scale innovation to Phase 1-ready GMP manufacturing—an essential step toward broader access to next-generation vaccines,” said Romulo Colindres, Chief Executive Officer of VitriVax. “Building GMP-compliant manufacturing capacity for innovative vaccine technologies is critical to ensuring that safe, effective vaccines can reach people around the globe. By working with a CDMO partner, we are not only preparing for first-in-human clinical studies but also laying the groundwork for scalable, reliable production that supports global public health priorities.”

ALTA^® is designed to stabilize antigens and adjuvants and enable co-formulation of otherwise incompatible components, with the goal of improving vaccine utility, compatibility, and supply resilience. Scale-up and qualification activities of the ALTA^® technology are intended to de-risk early clinical manufacturing and accelerate timelines from formulation to first-in-human studies.

About VitriVax

VitriVax, headquartered in Boulder, CO, has engineered its proprietary Atomic Layering Thermostable Antigen and Adjuvant (ALTA^®) technology platform to enable thermostable, single-shot vaccines across a broad range of indications while maintaining or potentially even enhancing the immune response of vaccines.  ALTA^® can be applied to a wide variety of vaccine antigens and adjuvants to protect against thermal and chemical degradation, enabling controlled release and incorporating prime doses and additional booster doses in a single-shot administration. These technologies may also facilitate the co-formulation of multiple, otherwise incompatible, antigens in a single injection.

Media Contact:

Julia Fuller

julia@fullercomms.com

(858) 692-2001

BOULDER, CO, APRIL 28, 2025 —VitriVax, Inc., a formulation technology company, announced a new grant of up to $5M from the Coalition for Epidemic Preparedness Innovations (CEPI). The grant will enable VitriVax to develop further the Atomic Layering Thermostable Antigen and Adjuvant (ALTA®) technology, using Rabies as a vaccine target. ALTA® could replace multi-dose vaccines for protection against infectious diseases with a single-administration alternative. The company’s innovative approach in the pharma industry, known as ‘atomic layering deposition’, is used to control the release of the vaccine in the body over time.

VitriVax is partnering with Serum Institute of India to explore whether the current three-dose Rabies vaccine, RabiVax-S, can be adapted using the ALTA^® platform to provide a single-administration, thermostable next-generation Rabies vaccine. The funded research will support preclinical and scale-up studies through GLP safety-toxicity testing to determine the immunogenicity, durability, and safety of the ALTA®-formulated RabiVax-S vaccine when compared to the current standard of care. If successful, the company will prepare the vaccine candidate for Phase I trials.

“CEPI funding will accelerate the advancement of our vaccine technology, particularly its application to the rabies immunization,” said Romulo Colindres, Chief Executive Officer of VitriVax. “We believe the ALTA^® platform has the potential to simplify the delivery of the vaccination by providing complete multi-dose protection in a single shot, as well as eliminate the need for cold chain storage. This is especially important in remote or resource-constrained regions where rabies remains a serious threat.”​

This is the latest vaccine project to be supported by CEPI’s call for vaccine innovations to tackle future epidemic and pandemic threats. Learnings from the research could be applied to other emerging infectious diseases that CEPI is focusing on, including a new or as-yet-identified ‘Disease X’, as well as other vaccine antigens and adjuvants.

“Receiving all the doses of protection you need in one go – with doses safely and slowly released over time – could be a game changer when it comes to effective outbreak response,” explains Dr Kent Kester, Executive Director of Vaccine Research and Development at CEPI. “As well as saving on costs, a multi-dose vaccine regimen delivered in a single shot would help ensure that more people are fully protected from a virus over time, helping to reduce the chance of repeat outbreaks and save more lives.

Further details on the announcement are available here.

About VitriVax

VitriVax, headquartered in Boulder, CO, has engineered its proprietary Atomic Layering Thermostable Antigen and Adjuvant (ALTA^®) technology platform to enable thermostable, single-shot vaccines across a broad range of indications while maintaining or potentially even enhancing the immune response of vaccines.  ALTA^® can be applied to a wide variety of vaccine antigens and adjuvants to protect against thermal and chemical degradation, enabling controlled release and incorporating prime doses and additional booster doses in a single-shot administration. These technologies may also facilitate the co-formulation of multiple, otherwise incompatible, antigens in a single injection.

Press Contact

Julia Fuller

Email: julia@fullercomms.com

Phone: +18586922001

BOULDER, COLORADO – December 4, 2024 – VitriVax, Inc., a vaccine formulation technology company, announced today a two-year $3.6 million grant from the Bill & Melinda Gates Foundation.  This is the second grant awarded to VitriVax by the Gates Foundation and will fund development of a polio vaccine formulation for possible inclusion in combination pediatric vaccines.

VitriVax will be applying its proprietary Atomic Layering Thermostable Antigen and Adjuvant (ALTA®) technology to new polio vaccine candidates composed of virus-like particles (VLPs) for use in future combination hexavalent vaccines. Use of VLPs as a modality in polio eradication efforts is under investigation for the next generation of polio vaccines. The ALTA® technology may facilitate the co-formulation of multiple, otherwise incompatible, antigens in a single injection.

“Funding support from the Bill & Melinda Gates Foundation allows us to continue our efforts to advance global accessibility to human vaccines,” said Romulo Colindres, CEO of VitriVax. “We are honored to be part of the global drive to protect children from polio infection and contribute to polio eradication efforts.”

About VitriVax

VitriVax, headquartered in Boulder, CO, is a vaccine formulation technology company that engineers innovative solutions to maximize global accessibility and utility of human vaccines – vaccines that save lives and protect our world from preventable disease.

Contact:
Anne King
anne.king@kingpr.net
(860) 415-3290

# # #

Grant from Gates Foundation funds manufacturing capacity expansion and platform technology research

BOULDER, COLORADO – December 6, 2023 – VitriVax, Inc., a formulation technology company, announced today a $5M two-year grant from the Bill & Melinda Gates Foundation.

The grant will allow the company to develop further its proprietary single shot, thermostabilization vaccine technology (ALTA) and begin the development of pilot-scale manufacturing capacity.  As part of the grant, the company will study the ALTA mechanism of action using model antigens, such as those targeting HIV.

The project will focus on formulation development, preclinical studies, and the development of Good Manufacturing Practice protocols to support future regulatory submissions.

“VitriVax, with funding from the Bill & Melinda Gates Foundation, is taking an important step forward in establishing its vaccine technology,” said Romulo Colindres, CEO of VitriVax.  “We are honored by the foundation’s support of our efforts to advance equitable access to vaccines around the world.”

About VitriVax

VitriVax, headquartered in Boulder, CO, has engineered its proprietary Atomic Layering Thermostable Antigen and Adjuvant (ALTA) technology platform to enable thermostable, single-shot vaccines across a broad range of indications while maintaining or potentially even enhancing the immune response of vaccines.  ALTA can be applied to a wide variety of vaccine antigens and adjuvants to protect against thermal and chemical degradation and enable controlled release, incorporating prime doses and additional booster doses in a single-shot administration.  These technologies may also facilitate the co-formulation of multiple, otherwise incompatible, antigens in a single injection.

Contact:

Anne King

anne.king@kingpr.net

(860) 415-3290

BOULDER, COLORADO – July 19, 2023 – VitriVax, Inc., a formulation technology company, has been awarded a $29M five-year contract by the Defense Threat Reduction Agency (DTRA), an agency within the U.S. Department of Defense.

The overall objective of the research proposal titled “Optimization and Production of Single-Shot Vaccines for Melioidosis and Glanders” is to apply VitriVax’s single-shot and thermostabilization technology (ALTA) to the lead B. pseudomallei (Bp) vaccine candidate, which is currently a three-dose regimen, with the goal of developing a single injection, thermostable vaccine formulation to protect against melioidosis and glanders. The project will focus on preclinical studies and development of Good Manufacturing Practice protocols, working toward an Investigational New Drug Application submission.

“We are excited about the opportunity to partner with DTRA and researchers at the University of Nevada, Reno, to bring our technology to a class of vaccines that will benefit both military personnel and the general population in regions where the disease is endemic,” said Kimberly D. Erickson, Ph.D., VitriVax’s Vice President of Operations and Principal Investigator.

VitriVax has built a strong research team consisting of formulation and analytical scientists, as well as particle engineers and manufacturing experts. They have strategically partnered with the University of Nevada, Reno, and the Latham BioPharm Group, Inc., to compile a support team of industry veterans with years of Bp vaccine development, government program management experience, and government contract compliance knowledge.

_________________________________________________________________________________________________________________________________________________________________

About VitriVax:  VitriVax, headquartered in Boulder, CO, has engineered its proprietary Atomic Layering Thermostable Antigen and Adjuvant (ALTA) technology platform to enable thermostable, single-shot vaccines across a broad range of indications, while maintaining or potentially even enhancing the immune response of vaccines. ALTA can be applied to a wide variety of vaccine antigens and adjuvants to protect against thermal and chemical degradation and enable controlled release, incorporating prime doses + additional booster doses in a single-shot administration. These technologies may also facilitate co-formulation of multiple, otherwise incompatible, antigens in a single injection.

Contact:  Anne King, anne.king@kingpr.net, 860 415 3290

VitriVax was selected out of more than 300 competing submissions to present a “Lightning Talk” at this year’s BARDA Industry Day.

BARDA (the Biomedical Advanced Research and Development Authority) hosts an annual Industry Day to increase potential partner’s awareness of U.S. Government medical countermeasure priorities, interact with BARDA and ASPR staff, and network with public and private sector colleagues working in the Health Security space.

Lightning Talks are designed to be brief, energetic, and full of information to pique the curiosity of industry and government colleagues and prospective partners.

To view presentations from the event click here: https://medicalcountermeasures.gov/barda/barda-industry-day-2020/

VitriVax is pleased to announce the publication of the paper “Single-Administration, Thermostable Human Papillomavirus Vaccines Prepared With Atomic Layer Deposition Technology” in the Nature journal npj Vaccines.

The study was funded in part by the NIH and the Bill & Melinda Gates Foundation, and was conducted in the University of Colorado laboratories of our co-founders, Bob Garcea and Ted Randolph.   The data demonstrate the effectiveness in mice of a single-shot human papillomavirus (HPV) vaccine using VitriVax’s groundbreaking vaccine formulation platform.

Traditional HPV vaccines require strict refrigeration to maintain their efficacy, and 2-3 doses must be administered over the course of months for full immunization.  The VitriVax formulated HPV vaccine demonstrated in this study is thermostable at over 50°C (122°F) for months without loss of efficacy.  Further, because the VitriVax combined dose technology provides timed release of a booster dose weeks after injection, only a single injection the VitriVax HPV vaccine formulation is required for full immunization.

“We’re thrilled to share the results of this exciting study.  The VitriVax platform’s ability to eliminate vaccine cold chain requirements, and to deliver multi-dose vaccines in a single injection can make an enormous impact for common public health vaccines like HPV, and it can also provide huge benefits in the fight against COVID-19 and other future pandemics” said VitriVax CEO, Matt Raider.

VitriVax is actively engaging in trials with multiple partners to demonstrate thermostability and combined doses for a variety of different antigens and disease targets, in both human and animal health.  Please reach out to us at info@vitrivaxbio.com if you have an antigen or vaccine candidate you’d like to discuss.

Link to the full paper at Nature.com